Feasibility, Acceptability, and Preliminary Evaluation of a User Co-Facilitated Psychoeducational Programme
BMC Psychiatry. 2024 Sep 16;24(1):615. doi: 10.1186/s12888-024-06015-4.
Background: Mental health settings are increasingly using co-facilitation of educational group interventions in collaboration with patient partners and service users. This study aimed to determine the feasibility, acceptability, and preliminary effects of a user co-facilitated psychoeducational group programme for adults diagnosed with ADHD.
Methods: The feasibility proof-of-concept randomised controlled trial recruited outpatients from a Norwegian community mental health centre. Outpatients randomised to the intervention group (IG) received a psychoeducational programme supplementing Treatment As Usual (TAU), while the control group received TAU. Feasibility was determined by the acceptance rate, adherence rate, and dropout rate. Acceptability was measured with the Client Satisfaction Questionnaire and a 3-item scale measuring satisfaction with the received information. To test the preliminary effects, self-efficacy, symptom severity, and quality of life were measured at baseline and pre- and post-intervention.
Results: Feasibility was demonstrated; most of the patients were willing to enrol, participants attended 82% of the psychoeducational programme, and only 13% dropped out of the study. The between-group analyses revealed that the IG reported significantly greater mean satisfaction than the CG. Moreover, the intervention group was more satisfied with the information they received during the psychoeducational programme. Concerning the preliminary effects, the linear mixed model showed improvement in quality of life (the subscale relationship); however, other patient-reported outcomes did not show improvements.
Conclusions: This proof-of-concept randomised controlled trial supports the feasibility and acceptability of the user co-facilitated psychoeducational programme for patients newly diagnosed with ADHD in an outpatient setting. While preliminary findings indicate promise in enhancing patient-reported outcomes, a larger study is warranted to assess the intervention’s effectiveness rigorously.
TRIAL REGISTRATION: NCT03425, 09/11/2017.
Clinical Trials and AI-Driven Solutions
Clinical trials are key to developing safe and effective treatments. It’s important to extend their benefits into everyday medical practice. DocSym, our AI-driven platform, helps by consolidating ICD-11 standards, clinical protocols, and research into a single, easily accessible knowledge base for clinicians.
In today’s healthcare environment, streamlining operations is crucial. Our mobile apps support scheduling, monitoring treatments, and telemedicine, making it easier to manage patient care and expand services digitally.
By using AI, clinics can enhance their workflows and improve patient outcomes, reduce paper routine. Learn more about how we can help at aidevmd.com.
